New Paper Details ‘Emerging and Accumulating’ Adverse Effects of ‘Gender Affirming’ Estrogen
Yet another group of scientists call for “rigorous further investigation” into “transgender” hormone interventions in a paper details new, adverse effects associated with giving men and boys “gender affirming” estrogen.
Unproven, opposite-sex hormone treatments wreak havoc the body and the brain. Estrogen consumption among men and boys has long been associated with infertility, testicular atrophy, cognitive decline and increased risk of testicular cancer, dementia, venous thromboembolism and stroke.
Despite these risks, and with an astonishing lack of testing and research, doctors across the globe have been administering opposite-sex hormones to adults and children with sexual identity confusion.
“Beyond previously identified harms associated with estrogen use by [natal men], many new safety signals are emerging, [including] exacerbation of some previously identified harms associated with long-term [estrogen] use,” psychiatrist Lauren Schwartz and experts from Genspect and the Society for Evidence-Based Gender Medicine write in their new paper, “Emerging and accumulating safety signals for the use of estrogen among [natal men].”
In pharmacology, “safety signals” refer to “information suggesting a previously unknown, potentially causal, association between a medicine and an adverse event.” Scientists document these signals to evaluate the ongoing effectiveness and safety of treatments.
The paper lays out several emerging “safety signals” plausibly related to men taking estrogen, including increased risk of:
- Death
A Dutch study of more than five decades-worth of patients at the Amsterdam gender identity clinic found biological men that took opposite-sex hormones died earlier than women and men who did not take opposite-sex hormones, most frequently from cardiovascular disease and cancer. - Developing or worsening autoimmune diseases
One man with an autoimmune disease affecting his skin experienced a life-threatening manifestation in his kidneys after he began taking estrogen. - Diabetes
Estrogen decreases lean mass, increases fat mass and worsens insulin resistance in men. - Pancreatitis
Estrogen can increase triglyceride levels, which are associated with pancreatitis and gallstone pancreatitis - Thyroid cancer
- Breast cancer
Higher levels of estrogen are associated with breast cancer development in men. - Developing cancerous neoplasms or experiencing cardiovascular anomalies after taking certain medications.
Schwartz and company dedicate a large section of the paper to the effects of estrogen on the male brain, which evolutionary biologist Colin Wright summarizes in an article for City Journal.
“Estrogen and testosterone blockers reduced brain volume and altered brain chemistry,” Wright paraphrases, noting the same effects occurred when scientists fed male rates estrogen.
Estrogen consumption in men is also associated with declining Brain-Derived Neurotrophic Factor (BDNF) — a chemical Wright describes as “critical to mood and memory.” BDNF decline not only elevates risk for developing major depressive disorder but decreases the size of the hippocampus and damages the brain’s frontal lobe, grey and white matter.
These cases, Schwartz and company emphasize, need not be conclusively linked to “gender affirming” estrogen to be highly concerning.
“Even if causality cannot (perhaps yet) be firmly established, adverse effects must be reported to communicate potential risks to clinicians and patients … and to motivate further investigating,” Schwartz writes, continuing:
But experts in “gender affirming” care demonstrate suspicious reluctance not only to evaluate their treatments, but inform patients of their considerable risks. The paper assesses:
It points to doctors like Stephen M. Rosenthal, the co-founder and medical director of the University of San Francisco’s Child and Adolescent Gender Center, who maintains there are “no clinically significant effects with gender-affirming sex hormones.”
Rosenthal was one of several transgender “experts” the federal government has paid to inject healthy children with opposite-sex hormones.
Dr. Richard Ogden Roberts of Texas Children’s Hospital (TCH) repeated a similar line to Rosenthal’s at a prestigious medical lecture in 2023, claiming, “Gender-affirming hormone therapy overall appears to be safe and effective.”
Roberts was later identified as one of at least two doctors performing transgender medical interventions on children long after TCH claimed to have shut down its transgender program.
The common thread here is profit. Those who make the most money from “gender affirming” hormone treatments consistently minimize concerns from the wider medical community about performing unproven, irreversible experiments on children.
The Daily Citizen applauds Shwartz, her colleagues, Genspect and the Society for Evidence-Based Gender Medicine for defending medical ethics.
Additional Articles and Resources
FBI Investigates Three Major Hospitals for Mutilating Children
INVESTIGATION: Taxpayers Fund Transgender Experiments on Children
HHS Releases Report on Harms of ‘Transgender’ Medical Interventions for Minors
New Research: 50-Fold Increase in ‘Gender Dysphoria’ in UK
Doctor Refuses to Publish Major Study Finding Puberty-Blocking Drugs Don’t Help Children
UPDATE: Evidence Reveals DOJ Oversight in Haim Case
England’s NHS Stops Dispensing Puberty Blockers for Children — Not Safe or Effective
